Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).

被引：1
|
作者：
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Daver, Naval Guastad
Kadia, Tapan M.
Konopleva, Marina
Jain, Nitin
Short, Nicholas James
Issa, Ghayas C.
Jeanis, Vicky
Moore, H. Gal
Garris, Rebecca S.
Garcia-Manero, Guillermo
Cortes, Jorge E.
O'Brien, Susan Mary
Jabbour, Elias
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif Irvine, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7025
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Hyper-CVAD Plus Ponatinib Versus Hyper-CVAD Plus Dasatinib as Frontline Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis
    Sasaki, Koji
    Jabbour, Elias J.
    Ravandi, Farhad
    Short, Nicholas J.
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Jain, Nitin
    Issa, Ghayas C.
    Jeanis, Vicki
    Moore, Haim G.
    Garris, Rebecca S.
    Pemmaraju, Naveen
    Cortes, Jorge E.
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    CANCER, 2016, 122 (23) : 3650 - 3656
  • [2] Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Short, Nicholas James
    Issa, Ghayas C.
    Garris, Rebecca S.
    Jeanis, Vicky
    Moore, H. Gal
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Gachimova, Evguenia
    O'Brien, Susan Mary
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib
    Sasaki, Yuya
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Jain, Nitin
    Sasaki, Koji
    Ravandi, Farhad
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Little, Latasha
    Gumbs, Curtis
    Zhao, Li
    Futreal, P. Andrew
    Wang, Feng
    Furudate, Ken
    Garris, Rebecca
    Takahashi, Koichi
    Jabbour, Elias
    BLOOD, 2020, 136
  • [4] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas
    Daver, Naval
    Pemmaraju, Naveen
    Thomas, Deborah
    Yilmaz, Musa
    Kadia, Tapan
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Weirda, William
    Jeanis, Vicky
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
  • [5] Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
    Yuya Sasaki
    Hagop M. Kantarjian
    Nicholas J. Short
    Feng Wang
    Ken Furudate
    Hidetaka Uryu
    Rebecca Garris
    Nitin Jain
    Koji Sasaki
    Farhad Ravandi
    Marina Konopleva
    Guillermo Garcia-Manero
    Latasha Little
    Curtis Gumbs
    Li Zhao
    P. Andrew Futreal
    Koichi Takahashi
    Elias Jabbour
    Leukemia, 2022, 36 : 1253 - 1260
  • [6] Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
    Sasaki, Yuya
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Wang, Feng
    Furudate, Ken
    Uryu, Hidetaka
    Garris, Rebecca
    Jain, Nitin
    Sasaki, Koji
    Ravandi, Farhad
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Little, Latasha
    Gumbs, Curtis
    Zhao, Li
    Futreal, P. Andrew
    Takahashi, Koichi
    Jabbour, Elias
    LEUKEMIA, 2022, 36 (05) : 1253 - 1260
  • [7] Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
    Yuya Sasaki
    Hagop M. Kantarjian
    Nicholas J. Short
    Feng Wang
    Ken Furudate
    Hidetaka Uryu
    Rebecca Garris
    Nitin Jain
    Koji Sasaki
    Farhad Ravandi
    Marina Konopleva
    Guillermo Garcia-Manero
    Latasha Little
    Curtis Gumbs
    Li Zhao
    P. Andrew Futreal
    Koichi Takahashi
    Elias Jabbour
    Leukemia, 2022, 36 : 1448 - 1448
  • [8] A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Othman, Tamer
    Moskoff, Benjamin
    Tenold, Matthew
    Azenkot, Tali
    Krackeler, Margaret
    Fisch, Samantha C.
    Potter, Laura A.
    Kaesberg, Paul R.
    Welborn, Jeanna
    Wun, Ted
    Esteghamat, Naseem
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Abedi, Mehrdad
    Tuscano, Joseph
    Jonas, Brian A.
    BLOOD, 2021, 138
  • [9] Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
    Sasaki, Koji
    Kantarjian, Hagop M.
    Morita, Kiyomi
    Short, Nicholas J.
    Konopleva, Marina
    Jain, Nitin
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Wang, Sa
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Champlin, Richard E.
    Khouri, Issa F.
    Kebriaei, Partow
    Schroeder, Heather M.
    Khouri, Maria
    Garris, Rebecca
    Takahashi, Koichi
    O'Brien, Susan M.
    Jabbour, Elias J.
    CANCER, 2021, 127 (18) : 3381 - 3389
  • [10] Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Short, Nicholas J.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang, Xuelin
    Daver, Naval G.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    Pemmaraju, Naveen
    Wierda, William G.
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Cortes, Jorge E.
    Garris, Rebecca
    Ward, Marygrace
    Huang, Binru
    Encarnacion, Corabelle
    Loiselle, Christopher
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Jain, Nitin
    Alvarez, Joie
    Tippett, Nicole
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2019, 134
12345